Is Lenvatinib (Lenvatinib) a targeted drug or an immune drug? What type of treatment does it belong to?

Lenvatinib is an oral multi-target tyrosine kinase inhibitor. It is a targeted drug that mainly works by inhibiting multiple tyrosine kinases. The main tyrosine kinases it targets include **VEGFR (vascular endothelial growth factor receptor), FGFR (fibroblast growth factor receptor), PDGFR (platelet-derived growth factor receptor)**, etc. These receptors play a key role in tumor cell proliferation, angiogenesis, tumor growth and metastasis. Lenvatinib inhibits the growth and spread of tumors by inhibiting the activity of these receptors and reducing the blood supply to tumors.

Lenvatinib works through a multi-target mechanism. It not only inhibits tumor cell proliferation, but also reduces tumor blood vessel supply by blocking angiogenesis signals, thereby limiting tumor growth. Lenvatinib's inhibitory effect on multiple receptors makes it potentially useful in the treatment of multiple tumor types, including hepatocellular carcinoma, renal cell carcinoma, thyroid cancer, and others. Lenvatinib can effectively improve patient survival and quality of life when treating these tumors.

Although lenvatinib has a certain effect on regulating the immune microenvironment, it is not an immunotherapy drug. Immunological drugs mainly attack tumor cells by enhancing the patient's immune system, while lenvatinib works by directly inhibiting tyrosine kinases related to tumor growth. Immunotherapy drugs such as immune checkpoint inhibitors (such as PD-1/PD-L1 inhibitors) regulate the function of the immune system and activate immune cells such as T cells to attack tumors, while lenvatinib directly acts on the signaling pathways of tumor cells themselves.
Lenvatinib, as a targeted therapy drug, has been approved by the FDA for the treatment of a variety of tumors, especially hepatocellular carcinoma (used in combination with sorafenib), renal cell carcinoma, thyroid cancer, etc. It controls disease progression by inhibiting tumor angiogenesis and tumor cell proliferation. The therapeutic effect of lenvatinib has been verified in multiple clinical studies, showing strong anti-tumor activity and good safety. When used in combination with other drugs, such as with immune drugs, lenvatinib can also enhance the therapeutic effect, providing patients with more treatment options.
Reference: https://www.lenvima.com/